Selective and Reversible Ligand Assembly on the DNA and RNA Repeat Sequences in Myotonic Dystrophy

Area of Science:

• Medicinal Chemistry
• Molecular Biology
• Genetics

Background:

• Small molecule targeting of DNA and RNA is a developing therapeutic strategy.
• Myotonic dystrophy type 1 (DM1) is a trinucleotide repeat disease driven by toxic RNA gain-of-function.

Purpose of the Study:

• To develop a novel method for in situ assembly of therapeutic agents targeting specific nucleic acid sequences.
• To investigate the efficacy of these agents in inhibiting toxic RNA formation and rescuing cellular defects in DM1.

Main Methods:

• Synthesis and screening of small molecules functionalized with aldehyde or amine groups.
• Confirmation of fragment assembly using MALDI-MS in the presence of DM1-relevant nucleic acid sequences.
• In vitro and cellular assays to assess inhibition of r(CUG)exp formation and rescue of mis-splicing defects.

Main Results:

• Successful synthesis and confirmation of reversible template-selected assembly of small molecules.
• Inhibition of toxic r(CUG)exp RNA formation in vitro by combined aldehyde and amine agents.
• Rescue of mis-splicing defects in DM1 model cells by the assembled therapeutic agents.

Conclusions:

• Reversible template-selected assembly is a viable strategy for in situ synthesis of therapeutic agents.
• This approach enables cell-permeable, multivalent targeting of nucleic acids.
• The method holds potential for treating DM1 and other nucleic acid-related diseases.